Major depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing to treatment-resistant depression (TRD).

A study of depressed individuals found that an eight‐week treatment with selective serotonin reuptake inhibitors (SSRIs) ...

IntroductionMajor depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing ...

Australians will wait an average of 12 years before getting treatment for mental health or substance use disorders, according ...

Supernus Pharmaceuticals may have had a potential path forward for its depression drug candidate cut off after the asset ...

Ketamine, a non-competitive N-methyl-D-aspartate receptor antagonist, has emerged as an effective therapeutic agent for the management of treatment-resistant depression. Repeated treatments with ...

A two-part clinical trial led by University of Cincinnati researchers at the Lindner Center of HOPE is testing the use of ...

The Royal Devon University Healthcare NHS Foundation Trust is leading ground-breaking clinical research that has the potential to transform treatments for neuropsychiatric disorders.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) revealed the topline data from the Phase 2b study of SPN-820 in adults with ...

Wearables could soon help detect changes in your mood, helping spot symptoms of depression and offering solutions.

Tracey Wade outlines several key issues to consider in developing successful early intervention approaches for people with disordered eating ...